Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients

Deborah Yamamura, Rasim A. Gucalp, Penelope Carlisle, Michael Cimino, Jeremy Roberts, Coleman Rotstein

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

An open-label randomized trial comparing the efficacy and safety of cefepime versus piperacillin plus gentamicin (P+G) given intravenously for the treatment of febrile episodes in neutropenic patients with underlying malignancy was conducted at two oncology centers. Over a 30-month period 111 patients were enrolled and 99 patients were found to be suitable for evaluation. At the 72-h time of evaluation, cefepime monotherapy and P+G combination therapy produced comparable clinical response rates (78% for both). P+G and cefepime produced comparable response rates in microbiologically documented (78 versus 71%), clinically documented (100 versus 100%); and possible (75 versus 79%) infections. The P+G and cefepime treatments achieved comparable microbiological eradication of gram-negative (100 versus 71%) (P = 0.09) and gram-positive (44 versus 70%) (P = 0.37) organisms. There were no statistically significant differences in the rates of superinfection between the groups; however, more superinfections of fungal origin were noted in the P+G group. Cefepime was demonstrated to be an effective and safe treatment for febrile episodes in neutropenic patients with malignancies, and its lack of nephrotoxicity compared to P+G was noteworthy. Cefepime appears to be a candidate for monotherapy in febrile neutropenic cancer patients.

Original languageEnglish (US)
Pages (from-to)1704-1708
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume41
Issue number8
StatePublished - Aug 1997

Fingerprint

Piperacillin
Gentamicins
Fever
Neoplasms
Superinfection
Therapeutics
cefepime
Safety
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. / Yamamura, Deborah; Gucalp, Rasim A.; Carlisle, Penelope; Cimino, Michael; Roberts, Jeremy; Rotstein, Coleman.

In: Antimicrobial Agents and Chemotherapy, Vol. 41, No. 8, 08.1997, p. 1704-1708.

Research output: Contribution to journalArticle

Yamamura, Deborah ; Gucalp, Rasim A. ; Carlisle, Penelope ; Cimino, Michael ; Roberts, Jeremy ; Rotstein, Coleman. / Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. In: Antimicrobial Agents and Chemotherapy. 1997 ; Vol. 41, No. 8. pp. 1704-1708.
@article{1ec082535f33437a8daee818b3e3b828,
title = "Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients",
abstract = "An open-label randomized trial comparing the efficacy and safety of cefepime versus piperacillin plus gentamicin (P+G) given intravenously for the treatment of febrile episodes in neutropenic patients with underlying malignancy was conducted at two oncology centers. Over a 30-month period 111 patients were enrolled and 99 patients were found to be suitable for evaluation. At the 72-h time of evaluation, cefepime monotherapy and P+G combination therapy produced comparable clinical response rates (78{\%} for both). P+G and cefepime produced comparable response rates in microbiologically documented (78 versus 71{\%}), clinically documented (100 versus 100{\%}); and possible (75 versus 79{\%}) infections. The P+G and cefepime treatments achieved comparable microbiological eradication of gram-negative (100 versus 71{\%}) (P = 0.09) and gram-positive (44 versus 70{\%}) (P = 0.37) organisms. There were no statistically significant differences in the rates of superinfection between the groups; however, more superinfections of fungal origin were noted in the P+G group. Cefepime was demonstrated to be an effective and safe treatment for febrile episodes in neutropenic patients with malignancies, and its lack of nephrotoxicity compared to P+G was noteworthy. Cefepime appears to be a candidate for monotherapy in febrile neutropenic cancer patients.",
author = "Deborah Yamamura and Gucalp, {Rasim A.} and Penelope Carlisle and Michael Cimino and Jeremy Roberts and Coleman Rotstein",
year = "1997",
month = "8",
language = "English (US)",
volume = "41",
pages = "1704--1708",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients

AU - Yamamura, Deborah

AU - Gucalp, Rasim A.

AU - Carlisle, Penelope

AU - Cimino, Michael

AU - Roberts, Jeremy

AU - Rotstein, Coleman

PY - 1997/8

Y1 - 1997/8

N2 - An open-label randomized trial comparing the efficacy and safety of cefepime versus piperacillin plus gentamicin (P+G) given intravenously for the treatment of febrile episodes in neutropenic patients with underlying malignancy was conducted at two oncology centers. Over a 30-month period 111 patients were enrolled and 99 patients were found to be suitable for evaluation. At the 72-h time of evaluation, cefepime monotherapy and P+G combination therapy produced comparable clinical response rates (78% for both). P+G and cefepime produced comparable response rates in microbiologically documented (78 versus 71%), clinically documented (100 versus 100%); and possible (75 versus 79%) infections. The P+G and cefepime treatments achieved comparable microbiological eradication of gram-negative (100 versus 71%) (P = 0.09) and gram-positive (44 versus 70%) (P = 0.37) organisms. There were no statistically significant differences in the rates of superinfection between the groups; however, more superinfections of fungal origin were noted in the P+G group. Cefepime was demonstrated to be an effective and safe treatment for febrile episodes in neutropenic patients with malignancies, and its lack of nephrotoxicity compared to P+G was noteworthy. Cefepime appears to be a candidate for monotherapy in febrile neutropenic cancer patients.

AB - An open-label randomized trial comparing the efficacy and safety of cefepime versus piperacillin plus gentamicin (P+G) given intravenously for the treatment of febrile episodes in neutropenic patients with underlying malignancy was conducted at two oncology centers. Over a 30-month period 111 patients were enrolled and 99 patients were found to be suitable for evaluation. At the 72-h time of evaluation, cefepime monotherapy and P+G combination therapy produced comparable clinical response rates (78% for both). P+G and cefepime produced comparable response rates in microbiologically documented (78 versus 71%), clinically documented (100 versus 100%); and possible (75 versus 79%) infections. The P+G and cefepime treatments achieved comparable microbiological eradication of gram-negative (100 versus 71%) (P = 0.09) and gram-positive (44 versus 70%) (P = 0.37) organisms. There were no statistically significant differences in the rates of superinfection between the groups; however, more superinfections of fungal origin were noted in the P+G group. Cefepime was demonstrated to be an effective and safe treatment for febrile episodes in neutropenic patients with malignancies, and its lack of nephrotoxicity compared to P+G was noteworthy. Cefepime appears to be a candidate for monotherapy in febrile neutropenic cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0030802949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030802949&partnerID=8YFLogxK

M3 - Article

C2 - 9257745

AN - SCOPUS:0030802949

VL - 41

SP - 1704

EP - 1708

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -